|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Patients most likely to benefit from PAI-1 inhibition would be those at high risk for vascular events where PAI-1 is elevated, such as is observed in obesity, diabetes and the metabolic syndrome.
|
17896948 |
2007 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Elevated plasminogen activator inhibitor-1 may contribute to vascular disease in diabetes mellitus.
|
8960834 |
1996 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
A multiple linear regression model with independent variables (age, body-mass index, total cholesterol level, triglyceride level, ACE I/D genotype, and PAI-1 genotype due to a single guanine I/D polymorphism in the PAI-1 gene) demonstrated that the triglyceride level (P = 0.0059) and ACE I/D genotype (P = 0.0372) were independent predictors of plasma PAI-1 antigen levels in a subset of the subjects without diabetes mellitus that were not taking lipid-lowering drugs.
|
10759003 |
2000 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Interaction between genotype and diabetes status was estimated for nine CVD risk factors [body fat mass (FAT), body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), log-transformed fibrinogen, log-transformed triglycerides, log-transformed urinary albumin : creatinine ratio (LACR), plasminogen activator inhibitor 1 (PAI-1), systolic blood pressure (SBP), and waist-to-hip ratio (WHR)], using a maximum likelihood variance decomposition technique.
|
12673782 |
2003 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
In 45/112 patients without the established risk factors for RVO (hyper-tension, hypercholesterolemia and diabetes) or characteristics known to be associated to increased PAI-1 activity (overweight, hypertriglyceridemia, and smoking habit) the contemporary presence of ACE DD and PAI-1 4G4G genotype was significantly associated with a risk for RVO (OR = 8.26, 95% CI 1.18-57.92; p = 0.034).
|
15213845 |
2004 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Low-moderate arsenic exposure was positively associated with baseline fibrinogen in participants with diabetes and unexpectedly inversely associated with PAI-1.
|
28771557 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
From our longitudinal cohort study, we selectively recruited chronically stable HIV-infected individuals without diagnosis of diabetes mellitus at baseline (N = 62) to analyze the correlation of baseline inflammatory cytokines, including PAI-1 and whole-body insulin sensitivity, with 2-year follow-up, as measured by Matsuda Index.
|
28322572 |
2017 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
PAI-1 activity was increased in hyperlipidemic compared to healthy dogs, but there was no significant difference between dogs with hyperadrenocorticism and diabetes mellitus.
|
28266313 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice.
|
25552599 |
2015 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The PAI-1 and ACE (D/I) gene polymorphisms were examined in a cohort of Chinese type 2 diabetic patients who had diabetes for an average of 14 years.
|
10652041 |
2000 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Increased levels of PAI-1 and glycated low-density lipoprotein (glyLDL) were detected in patients with diabetes.
|
20630999 |
2010 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
This study investigated PAI-1 serum level and MMP-3 activity and their correlation with glomerular filtration rate in patients with diabetes mellitus.
|
29421776 |
2018 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
|
21070757 |
2011 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Elevated PAI-1 levels may be associated with an increased risk for diabetes as a marker for underlying endothelial dysfunction rather than by a direct effect of genetically mediated elevated levels.
|
16855181 |
2006 |